About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, December 6th, 2017

The QualityStocks
Daily Stock List


Glance Technologies, Inc. (GLNNF)

InvestorsHub, MarketWatch, Evergreen Caller, and Emerging Growth reported on Glance Technologies, Inc. (GLNNF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Glance Technologies, Inc. owns and operates Glance Pay. This is a streamlined payment system. It transforms how smartphone users choose where to dine, order food and drink, settle bills, access digital receipts, earn premier rewards, and interact with merchants. Concerning the Glance Pay mobile payment app, there is no set up or cancellation fees and no system integration or connections required. OTCQB-listed, Glance Technologies is based in Vancouver, British Columbia.

The Glance Pay mobile payment app works for full service restaurants, quick serve, retail, and more. Moreover, it features easy activation and training and easy automatic accounting and reconciliation, and fast payment deposits. Servers and managers can review transaction details.

Glance Technologies is building a valuable network of merchants and consumers. The Company offers targeted in-app marketing, social media marketing, customer feedback, in-merchant messaging, and custom rewards programs.

The Glance Pay mobile payment system consists of proprietary technology. This technology includes user apps available for free downloads in IOS (Apple) and Android formats, a merchant manager apps, a large-scale technology hosting environment with sophisticated anti-fraud technology, and very fast payment processing.

Glance Technologies earlier agreed to license its mobile payment technology to Active Pay Distribution, Inc. for $1,000,000. This marks Glance Technologies’ entry into the fitness and wellness market.

With the deal, Glance Pay will create and provide the technology backbone for the Active Pay app, which will serve the growing fitness and wellness community. The app will be called Active Pay. It will be uniquely branded as Active Pay. Nonetheless, it will be labeled as "powered by Glance Pay".

Glance Technologies plans to launch a "Glance" token that will be granted as a reward to users of the Glance Pay mobile payment app every time they make a payment on the Glance Pay mobile network. The reward will apply to all payments, whether the payment is made with the new cryptocurrency or by other payment methods. In addition, the Company intends to apply elements of its anti-fraud technology to cryptocurrencies to lessen the risk associated with converting traditional currencies to and from cryptocurrencies.

Glance Technologies has entered into a non-binding Letter of Intent (LOI) to acquire Blockimpact from Ztudium Limited. Blockimpact is a blockchain and cryptocurrency with a rewards tokenization platform. With this LOI, Glance will acquire all of the intellectual property (IP) consisting of the Blockimpact platform for a cost of US$1.1 million. Blockimpact is a full end-to-end cryptocurrency blockchain solution.

Glance Technologies, Inc. (GLNNF), closed Wednesday's trading session at $1.97, down 5.79%, on 1,819,333 volume with 1,307 trades. The average volume for the last 60 days is 2,625,304 and the stock's 52-week low/high is $0.11/$3.20.

Zynex, Inc. (ZYXI)

TaglichBrothers, Zacks, SmarTrend Newsletters, FeedBlitz, BUYINS.NET, FNNO Newsletters, Daily Markets, and SmallCapVoice reported previously on Zynex, Inc. (ZYXI), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Zynex, Inc. is a medical technology company headquartered in Lone Tree, Colorado. The Company specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring. Additionally, Zynex is developing a new blood volume monitor for use in hospitals and surgery centers. Established in 1996, Zynex lists on the OTC Markets’ OTCQB.

Zynex’s product lines are completely developed, Food and Drug Administration (FDA)-cleared, and commercially sold around the world. Zynex engineers, manufactures, markets, and also sells its own design of medical devices in three subsidiaries.

Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets. Zynex Medical is a provider of electrotherapy products for home use. Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals.

Zynex markets and sells its own design of electrotherapy medical devices utilized for pain management and rehabilitation. Furthermore, the Company markets and sells its proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients.

In March 2015, Zynex announced that it submitted a Pre-Submission application to the FDA for its non-invasive Blood Volume Monitor, CM-1500. Zynex’s belief is that this will be the first device to provide an indication of fluid balance and blood loss in the operating room or potential post-surgical internal bleeding in recovery.

The Company announced in September 2015 that its wholly-owned subsidiary, Zynex Monitoring Solutions, filed an application with the FDA pursuant to Section 510(k) of the Food, Drug and Cosmetic Act for clearance of its new CM-1500 monitoring device.

Zynex continues to introduce a number of new products to its product portfolio. This is to address the pain and rehabilitation markets and the current opioid epidemic.

New products the Company has added include JetStream Hot/Cold Therapy, Aspen LSO Backbracing and Comfortrac cervical traction. All of these products are targeted at treating acute and chronic pain without side-effects.

Recently, Zynex announced that it has leased new office space. The Company will be moving its corporate headquarters to Englewood, Colorado.

The new building is less than one mile from the Company’s current headquarters. It will increase the footprint from about 17,000 square feet to about 43,800 square feet with a first right of refusal to occupy more space in the building.. The lease is for 66 months. The lease can be extended by another two years until June 30, 2025.

Zynex, Inc. (ZYXI), closed Wednesday's trading session at $2.25, up 10.84%, on 143,126 volume with 199 trades. The average volume for the last 60 days is 39,958 and the stock's 52-week low/high is $0.25/$3.25.

Research Solutions, Inc. (RSSS)

Marketbeat and Wall Street Resources reported on Research Solutions, Inc. (RSSS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Research Solutions, Inc. is an innovator in providing cloud-based solutions for scientific research. The Company is a pioneer in cloud-based SaaS (Software-as-a-Service) research intelligence products and services for research-intensive organizations. The Company’s cloud-based SaaS platform provides customers with on demand access to, and augmented data from, tens of millions of scientific, medical, and technical (STM) documents. This is in addition to tens of millions of articles beforehand published. Research Solutions is based in Encino, California.

Research Solutions has its wholly-owned subsidiary Reprints Desk, Inc. Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions, medical affairs, and scientific, technical, and medical (STM) research.

Reprints Desk and Altmetric LLP previously agreed to integrate Altmetric badges to scholarly content obtained through Reprints Desk's award-winning research retrieval platform Article Galaxy. Altmetric is a foremost research metrics provider.

Reprints Desk has signed separate reseller agreements with Ritme and Alfasoft to deliver new tools and services, which address the complete range of knowledge acquisition and information management requirements of researchers in scientific, technical, and medical (STM) fields.

In November, Research Solutions announced that its wholly-owned subsidiary, Reprints Desk, was named to EContent Magazine's list of 100 digital content industry leaders for the seventh consecutive year in the Distribution and Delivery category. EContent Magazine's annual list is decided by a panel of eleven information industry experts. They select the 100 most influential organizations from thousands of candidates in the fast changing digital content creation and delivery industry.

Also in November, Research Solutions reported financial results for its fiscal Q1 ended September 30, 2017. The Reprints and ePrints business was sold on June 30, 2017. It is classified as a discontinued operation.

For Fiscal Q1 2018 versus the year-ago quarter, total revenue grew 9 percent to $6.7 million. Platform revenue was up 126 percent to $388,000, with a 115 percent increase in total Platform deployments to 161. Annual recurring revenue rose 112 percent to $1.6 million.

The Company’s transaction revenue grew 6 percent to $6.4 million. Customer count increased 9 percent to 1,022. Transaction count increased 7 percent to 205,066. Total gross margin was up 270 basis points to 25.9 percent.

Net loss from continuing operations was $0.8 million, or $(0.04) per share. This is in comparison to a net loss of $0.5 million, or $(0.02) per share.

Research Solutions, Inc. (RSSS), closed Wednesday's trading session at $1.22, even for the day. The average volume for the last 60 days is 63,435 and the stock's 52-week low/high is $0.66/$1.325.

Independence Bancshares, Inc. (IEBS)

Zacks, MarketWatch, and Investors Hub reported on Independence Bancshares, Inc. (IEBS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

A South Carolina corporation, Independence Bancshares, Inc. operates as the bank holding company for Independence National Bank. The Bank provides diverse banking products and services, chiefly in Greenville County, South Carolina. Independence National Bank opened in May of 2005. It provides a comprehensive line of business and personal financial products. Independence Bancshares is headquartered in Greenville, South Carolina. The Company lists on the OTC Markets’ OTCQB.

Independence Bancshares was organized to operate as a bank holding company pursuant to the Federal Bank Holding Company Act of 1956 and the South Carolina Bank Holding Company Act, and to own and control all of the capital stock of Independence National Bank.

Independence National Bank has three locations. These are in Greenville, South Carolina; Taylors, South Carolina; and Simpsonville, South Carolina. The Bank primarily serves individuals, small business owners, legal and medical communities, insurance agencies, and clients owning and developing income producing properties.

The Bank accepts varied deposits products. These include checking accounts, commercial accounts, NOW accounts, savings accounts, and time deposits of different kinds ranging from daily money market accounts to long-term certificates of deposit.

Furthermore, the Bank offers commercial real estate loans, construction and development real estate loans, residential real estate loans and home equity loans, and commercial business loans, and also loans to individuals for personal and household purposes. This includes secured and unsecured installment loans and revolving lines of credit.

Moreover, it offers debit and credit card transactions, sales of checks, safe deposit boxes, wire transfers, automated teller machines (ATMs), merchant banking, online banking, bill payment, and cash management services. Additionally, Independence National Bank offers Mobile Banking. The Bank also provides cashier’s checks, banking by mail, direct deposit, remote deposit capture, United States savings bonds, bank official checks, and travelers’ checks services.

This past September, First Reliance Bancshares, Inc. (FSRL), parent of First Reliance Bank, announced the entry into a definitive agreement to acquire Independence Bancshares and its wholly-owned bank subsidiary, Independence National Bank. Under the terms of this merger agreement, Independence Bancshares shareholders will receive merger consideration in cash, for each share of IEBS.

First Reliance Bancshares is the holding company for First Reliance Bank. The Bank employs approximately 130 associates. It serves the Columbia, Lexington, Charleston, Mount Pleasant, Summerville, Loris, North Myrtle Beach, and Florence markets in South Carolina.

Independence Bancshares, Inc. (IEBS), closed Wednesday's trading session at $0.1208, down 0.17%, on 19,500 volume with 1 trade. The average volume for the last 60 days is 60,493 and the stock's 52-week low/high is $0.10/$0.42.

Lexington Biosciences, Inc. (LXGTF)

MarketWatch, Tech Stock Insider, and InvestorsHub reported on Lexington Biosciences, Inc. (LXGTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A medical device enterprise, Lexington Biosciences, Inc. is developing the HeartSentry. This is a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium. This is the essential innermost lining of a person's cardiovascular system.

The Company is engaged with the US FDA (Food and Drug Administration) and other regulatory agencies on the required product approvals for the HeartSentry. OTCQB-listed, Lexington Biosciences has offices in Vancouver, British Columbia; and Reno, Nevada.

The Company’s goal is to become a leader in the development of clinical grade cardiovascular self-measurement solutions for home and clinical use. The design of the HeartSentry unit is to use Bluetooth and Cloud technology to provide up-to-date and accurate readings of an individual’s complete cardiovascular health by way of electronic monitoring for risk-assessment and treatment effectiveness targeting the prevention of heart attack and stroke.

HeartSentry targets the fast growing self-measurement medical device sector. HeartSentry is the Company’s flagship, and first device presently advancing to commercial deployment. Lexington Biosciences recently announced delivery of its first order of HeartSentry devices scheduled for clinical trials.

Last week, Lexington Biosciences announced the engagement of San Francisco Bay Area-based Diablo Clinical Research to conduct its forthcoming HeartSentry pilot clinical studies. With this announcement, plans are now advancing to initiate the start of a pilot clinical research study designed to start gathering the foundational dataset targeted at supporting FDA clearance.

The HeartSentry core technology underwent development at the University of California Berkeley over a fifteen-year research and development (R&D) period involving numerous research studies and product iterations resulting in a portfolio of manifold pending and issued patents licensed to Lexington Biosciences.

The Company’s objective is to make HeartSentry accurate, fast, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health.

Mr. Eric Willis, Lexington Biosciences’ President, said, "After nine months of concerted effort by our design and production team, the arrival of our first human-use HeartSentry devices allows us to accelerate our plans to move ahead with our pilot study. Diablo Clinical Research is a proven and respected establishment with the capability to launch our research program efficiently and cost-effectively.”

Lexington Biosciences, Inc. (LXGTF), closed Wednesday's trading session at $0.4575, up 3.95%, on 468,419 volume with 141 trades. The average volume for the last 60 days is 253,895 and the stock's 52-week low/high is $0.2506/$0.484.

AmeriCann, Inc. (ACAN)

SmallCapVoice, Real Pennies, TopPennyStockMovers, Promotion Stock Secrets, Cannabis Financial Network News, OTC Markets Group, and TheMicrocapNews reported on AmeriCann, Inc. (ACAN), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

AmeriCann, Inc. is developing sustainable, state-of-the-art medical cannabis cultivation properties. The OTCQB-listed Company is a national leader of sustainable cultivation and processing infrastructure for the medical marijuana industry. It designs, builds, and owns efficient cultivation and processing facilities to produce medical cannabis. It is developing projects throughout the nation in regulated markets through the “Preferred Partner Program”.  An Agricultural Technology Company, AmeriCann is based in Denver, Colorado.

The Company identifies, acquires, and develops real estate particularly suited for cannabis operations. AmeriCann finances real estate development. In addition, it provides necessary venture capital to developing cannabis enterprises.

AmeriCann has a multi-market growth strategy with an existing portfolio of greater than 1,000,000 sq. ft. of sustainable cannabis production infrastructure in development. Its corporate mission is to serve medical cannabis patients through providing facilities designed and constructed to produce high quality, consistent medicine, cultivated and processed in a controlled, secure, and sustainable environment.

AmeriCann announced in June of this year that it completed a very successful three-year partnership with a licensed Colorado cannabis producer, which resulted in first-rate returns to the Company. AmeriCann contributed $1,000,000 in secured funding in 2014 for the final design and construction of a 15,000-square foot state-of-art cultivation and processing facility in Denver, Colorado. Its Preferred Partner, 4900 Jackson, LLC, has been a licensed medical cannabis producer in Colorado since 2010.

With the final payment made in May 2017, AmeriCann received total distributions over the term of the agreement of $1,457,000. This was from consulting fees, interest, as well as principal repayment. The average yearly returns exceeded 15 percent over the 3 years.

This past September, AmeriCann announced that Coastal Compassion, Inc. (CCI), its Preferred Partner in Massachusetts, received a Final Certificate of Registration from the Department of Public Health. CCI is one of a limited number of vertically integrated companies approved to cultivate, process and ultimately dispense medical cannabis in the Massachusetts Medical-Use of Marijuana program.

With the Final Certificate of Registration, CCI has all the approvals to begin cultivation in its fully-constructed Registered Marijuana Dispensary (RMD) located in Fairhaven, Massachusetts. The Fairhaven RMD will house CCI's first cultivation and processing operations and a permanent retail dispensary location.

Upon completion of the first building at AmeriCann's Massachusetts Medical Cannabis Center (MMCC) in Freetown, Massachusetts, CCI will relocate the cultivation and processing activities to the MMCC and maintain its retail dispensary in Fairhaven.

AmeriCann has agreements with Coastal Compassion to lease 100 percent of the first phase of MMCC that will comprise a 30,000 square foot greenhouse, laboratory and research center.

AmeriCann, Inc. (ACAN), closed Wednesday's trading session at $2.19, down 3.95%, on 74,949 volume with 158 trades. The average volume for the last 60 days is 40,499 and the stock's 52-week low/high is $0.90/$5.50.

Liberty Leaf Holdings Ltd. (LIBFF)

Stockhouse, MarketWatch, Barchart, and InvestorsHub reported on Liberty Leaf Holdings Ltd. (LIBFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Liberty Leaf Holdings Ltd.’s emphasis is to build and support a diversified portfolio of cannabis-sector businesses. This includes cultivation, cannabidiol (CBD)/tetrahydrocannabinol (THC) products, biotechnology research and supply-chain products within this fast-growing sector. Liberty Leaf Holdings has its corporate office in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Additionally, Liberty Leaf owns 100 percent of North Road Ventures. This is a late-stage applicant under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). Liberty Leaf acquired North Road Ventures in October of 2016.

North Road Ventures is a developing distributor of cultivated and manufactured cannabis products to licensed legal retailers. It is expanding into the recreational market.

Liberty Leaf works to acquire partnership interests in up-and-coming and established companies in the medicinal and recreational cannabis arena. It operates in Canada and is looking to enter the diverse legal cannabis markets in North America.

An active partner of Liberty Leaf Holdings is ESEV Genetics. ESEV is developing the world’s first genomic platform for high value crops and advancing medicine and foods plant-derived solutions.

Liberty Leaf’s subsidiary, North Road Ventures, has submitted a significant abridgement to its Access to Cannabis for Medical Purposes Regulations (ACMPR) application now in review by Health Canada. The abridgement, along with North Road's innovative new business plan, capitalizes on recent developments within the cannabis industry.

With this abridgement, North Road Ventures will have a distribution model that eases looming supply-chain issues, for "craft" or "artisan" licensed producers. Fundamentally, North Road Ventures is changing its application to become distribution-focused.

Last week, Liberty Leaf Holdings announced the appointment of Mr. Doug Macdonell to its Board of Directors. Mr. Macdonell is a retired RCMP officer. He is a recognized expert in the field of cannabis and cannabis cultivation.

During his wide-ranging RCMP career, Mr. Macdonell initiated and supervised legal marijuana grow facilities in Vancouver and Edmonton for training RCMP and City Police personnel to become specialists in the cannabis industry. He is also recognized as an expert witness in cannabis, cannabis production and distribution at all levels of the Canadian court system.

Liberty Leaf Holdings Ltd. (LIBFF), closed Wednesday's trading session at $0.2599, up 0.35%, on 139,600 volume with 25 trades. The average volume for the last 60 days is 46,089 and the stock's 52-week low/high is $0.0091/$0.2651.

Organigram Holdings, Inc. (OGRMF)

Cannabis Financial Network News, CFN Media Group, InvestorPlace, Wealth Daily, and Money Morning reported previously on Organigram Holdings, Inc. (OGRMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Organigram Holdings, Inc.’s emphasis is on producing the highest quality, condition specific medical marijuana for patients in Canada. The Company’s wholly-owned subsidiary, Organigram, Inc., is a licensed producer of medical marijuana in Canada. The Company's head office, production facility, and Research and Development (R&D) are in Moncton, New Brunswick. Organigram Holdings’ shares trade on the OTC Markets Group’s OTCQB.

Organigram Holdings is regulated by the Access to Cannabis for Medical Purposes Regulations (ACMPR). All of the Company’s products are manufactured under strict controls and in conformance with the Good Production Practices of the MMPR, and the security directives as defined by the Office of Controlled Substances. All products are lab tested before packaging and sale.

Organigram provides a varied array of genetics and product types. These cater to the individual needs of each and every client. Organigram offers a reliable supply of premier quality, industry-leading strains to match individuals’ personal needs.

Organigram has collaborations with healthcare experts and academic institutions. The Company invests in medical education, outreach, and research for the use of cannabinoids as a first line of treatment.

Organigram Holdings is undergoing a production-facility expansion. This expansion will more than triple the size of the Company’s operations. The multi-million-dollar project will meet the increasing needs of its medical patient base, and also prepare Organigram for the legal, adult-recreational marijuana market.

The highlights of the Company’s plans include the addition of about 140 new employees by the end of 2018; and an expansion of its existing production facility from 36,000 to 134,000 square feet by the end of 2017, grown on three levels.

Plans also include a further 36,000 square-foot expansion scheduled for completion by mid 2018; a production-capacity increase from roughly 5,200 kilograms (kg) per year to over 25,000 kg per year; and the acquisition of a third building at 55 English Drive for future expansion, next to the current campus.

Recently, Organigram announced that it started the process for re-certification as an organic producer of cannabis in Canada with ECOCERT Canada. As part of the process, Organigram submitted a comprehensive action plan to ECOCERT Canada, outlining its approach to the growing and segregation of both product lines. The design of the plan is to ensure the integrity of organic products within its facility, and was approved by ECOCERT Canada in September of this year. ECOCERT Canada is part of the Ecocert group, one of the largest organic certification organizations in the world.

Organigram Holdings, Inc. (OGRMF), closed Wednesday's trading session at $3.00, up 11.11%, on 392,916 volume with 704 trades. The average volume for the last 60 days is 224,530 and the stock's 52-week low/high is $1.35/$3.15.


The QualityStocks
Company Corner


Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.0715, up 2.14%, on 1,217,572 volume with 125 trades. The stock’s average daily volume over the past 60 days is 420,368, and its 52-week low/high is $0.0161/$0.20.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions to Launch New Website and Portal, Completes Rebrand of its Product Offering

Medical Cannabis Payment Solutions (REFG) is “One to Watch”

Medical Cannabis Payment Solutions (REFG) to Purchase Industry Leading Cryptocurrency, Launch Joint Venture Aimed at Alternative Payment Solution for the Cannabis Industry

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0725, up 133.87%, on 65,304,267 volume with 3,116 trades. The stock’s average daily volume over the past 60 days is 4,868,712, and its 52-week low/high is $0.009/$0.04.

Global Payout, Inc. (GOHE), CannabisNewsWire Editorial Coverage: As bitcoin’s price continues its meteoric rise, which has seen the cryptocurrency skyrocket in value from just under $1,000 at the start of 2017 to above $10,000 in November, a number of companies have taken steps to benefit from the growth of the burgeoning cryptocurrency industry. One area of the industry that appears to offer significant growth potential is the application of bitcoin and other cryptocurrencies to sectors of the economy, such as the cannabis industry, that are blocked from accessing banking services.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Bitcoin’s Rise Solidifies the Intersection of Cannabis and Cryptocurrency

MoneyTrac Technology, Inc.’s PotSaver to Create Effective Networking and Marketing Platform for Cannabis Businesses with Launch

MoneyTrac Technology, Inc. Establishes Key Partnership to Strengthen Sales & Marketing of Its Alternative Banking Solutions

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.7772, up 7.20%, on 197,487 volume with 74 trades. The stock’s average daily volume over the past 60 days is 124,214 and its 52-week low/high is $0.248/$2.119.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to report that engineering partner PurLucid Treatment Solutions (“PurLucid”) has partially commissioned the commercial-scale NFLi5 lithium recovery system at its new manufacturing facility in Calgary, Alberta. The pre-treatment nanoflotation and nanofiltration system is now operational with all electrical, control and pump systems in the first two stages of the process operational under constant flow. Additional mineral extraction nanofiltration components are expected to be brought online sequentially over the upcoming weeks and the system will be ready for deployment in early Q1 2018.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals and PurLucid Treatment Solutions Announce Initial Commissioning of Rapid Lithium Recovery System, Deployment Site and Water Processing Contract

MGX Minerals’ Joint Venture Partner Power Metals Samples up to 7.14% Li2O on Surface at Case Lake Lithium Property

MGX Minerals Engages Senator Richard Polanco (Ret.) to Direct California Lithium Brine Strategy

Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.1695, up 9.72%, on 146,172 volume with 50 trades. The stock’s average daily volume over the past 60 days is 85,257 and its 52-week low/high is $0.0711/$0.2419.

Tapinator, Inc. (TAPM),  NetworkNewsWire Editorial Coverage: A recently released report projects that revenue from the global mobile games market will reach $40.6 billion in 2017, which is an increase of more than $10 billion from 2015 (http://nnw.fm/d8LBZ). Mobile gaming is unarguably the hottest, fastest-growing sector within the gaming market, and traditional gaming companies are jumping in with big M&A action, buying up smaller creative players in order to develop expertise and market share in the mobile games arena.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

Mobile Gaming Acquisitions on Pace to Boom in 2018

Tapinator Announces Full-featured Games Pipeline Through Q1 2018

Virtual Mom: Happy Family 3D Surges to Become a Top 100 Mobile Game on Google Play

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (FTSSF). Today, Petroteq Energy Inc. closed trading at $1.70, up 1.29%, on 119,185 volume with 183 trades. The stock’s average daily volume over the past 60 days is 74,978, and its 52-week low/high is $0.015/$1.8892.

Petroteq Energy Inc. (TSXV: PQE; OTCQX: PQEFF; Frankfurt: A2DYWC), a company focused on the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits, announced today that it has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy Announces Membership in American Petroleum Institute

Petroteq Energy Announces Petrobloq's Membership in Enterprise Ethereum Alliance

OPEC extension promises faster payback period for Petroteq's Asphalt Ridge Plant

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.9283, off by 0.27%, on 630,964 volume with 418 trades. The stock’s average daily volume over the past 60 days is 826,489, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire Editorial Coverage: Cannabis derivatives have been used medicinally around the world for millennia. However, concerns surrounding potential dangers and abuse of marijuana’s psychoactive component THC (tetrahydrocannabinol) led to the banning of medicinal cannabis early in the 20th Century. Recent scientific studies, however, have given new credence to the wisdom from millennia ago and have scientifically proven the medical efficacy of certain cannabinoids for developing new approaches to treating diseases with high unmet medical needs. Global scientists, researchers, and biopharmaceutical companies are now focused on cannabinoids that have therapeutic potential. One pioneering biopharmaceutical company, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF profile), has triggered a paradigm shift in discovering potential breakthrough cannabinoid-based therapies.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management

Purified Cannabinoids Open New Opportunities in Pain Management

InMed to Present at Cannabis-Based Science & Medicine Conference

Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.374, even for the day, on 7,877 volume with 9 trades. The stock’s average daily volume over the past 60 days is 61,328, and its 52-week low/high is $0.131/$3.99.

Medical Innovation Holdings, Inc. (OTC: MIHI) subsidiary, Bkare Diagnostics, LLC will expand its offering to primary care physicians featuring AeonMD's ADAPT (Assessments, Diagnostics, and Preventative Therapies) Preventive Care patient assessment and diagnostics solutions. 

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

Medical Innovation Holdings, Inc. (OTC: MIHI) Announces a Strategic Arrangement With AeonMD, LLC, a Leading Provider of Wellness Therapies for Physician Offices

Medical Innovation Holdings to be Featured on National Radio Telecasted Tuesday October 24th, 2017 at 10AM ET on Beasley Broadcasting

NetworkNewsWire Announces Publication Highlighting Disruptive Business Models in Growing Telemedicine Sector

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.1012, off by 4.53%, on 21,436,522 volume with 1,341 trades. The stock’s average daily volume over the past 60 days is 8,193,109, and its 52-week low/high is $0.01/$0.415.

Smart Cannabis Corp (OTC PINK: SCNA) and SinglePoint, Inc. (OTC: SING) have signed a letter of intent to formalize a multi-faceted joint venture and co-marketing relationship for the cannabis market bringing cyber currency payment solutions together with our SMARTAPP automation software product, and soon-to-be-released "Track and Trace Software System," which will be a natural add-on extension to SinglePoint's current payment processing system.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

Smart Cannabis Corp and SinglePoint, Inc. Announce Joint Venture Expanding Blockchain Technology into SMARTAPP Automation Software for the Rapidly Growing Cannabis Market

SinglePoint and Smart Cannabis Corp. Sign Joint Venture to Integrate, Distribute ‘SMART APP’ for Cannabis Businesses

CannabisNewsWire Announces Publication Discussing Payment Processing Solutions for the Cannabis Marketplace


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(GOHE) +133.87%


Trader Power News
(VTGN) +95.65%


(MDGL) +88.29%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251